Fluminorex
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (RS)-5-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazol-2-amine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 720-76-3  |
| ATC code | None |
| PubChem | CID 24100 |
| ChemSpider | 22530 |
| UNII | LUO2Z7954T |
| KEGG | D04210 |
| Chemical data | |
| Formula | C10H9F3N2O |
| Mol. mass | 230.19 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Fluminorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s.[1]
[edit] See also
[edit] References
 |
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (September 2009) |
- ^ US Patent 3278382 - 2-amino-5-aryloxazoline compositions and methods of using same
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
